ArticleFrontiers in nutrition2026
Nutrient metabolic heterogeneity across renal stages in patients with type 2 diabetes mellitus and diabetic kidney disease.
Article in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Diabetic kidney disease (DKD) is a nutrition-related complication of type 2 diabetes mellitus (T2DM) characterized by complex disturbances in glucose, lipid, purine, and protein-related metabolism. This study aimed to investigate nutrient metabolic heterogeneity across renal stages in patients with T2DM and DKD, with particular focus on time in range (TIR), serum uric acid (SUA), TG/HDL-C ratio, and serum albumin (ALB). Methods: This single-center cross-sectional study included 589 hospitalized patients with T2DM, including 128 patients without DKD and 461 patients with DKD. DKD patients were further stratified according to KDIGO eGFR categories. Continuous glucose monitoring-derived TIR, SUA, TG/HDL-C ratio, and ALB were evaluated as multidimensional nutrient metabolism indicators. Multivariable logistic regression analyses were performed to identify independent metabolic indicators associated with DKD. Renal-stage trend analyses and stratified analyses in G3 and G5 were further conducted to explore stage-specific metabolic patterns. Results: Compared with patients without DKD, patients with DKD were older, had longer diabetes duration, and showed greater use of glucose-lowering and lipid-lowering medications. Patients with DKD also showed paradoxically higher TIR levels. In the overall multivariable model, higher TIR was associated with lower odds of DKD (OR = 0.97, 95% CI: 0.95-0.99, Conclusion: DKD in T2DM is characterized by stage-specific nutrient metabolic heterogeneity involving glucose, purine, lipid, and protein-related nutritional metabolism. G3 may represent a renal stage characterized by more prominent glucose, uric acid, and lipid metabolic abnormalities, whereas G5 may be characterized by more evident nutritional deterioration. These findings should be interpreted as stage-specific associations rather than causal progression pathways because of the cross-sectional design. Clinical trial registration: https://www.chictr.org.cn/bin/home, identifier ChiCTR2500111406.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.